Life Science Investing Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care' 10 October
Life Science Investing Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program 02 October
Life Science Investing Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia 02 October
